Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 11, 2013 - Issue 3
Submit an article Journal homepage
338
Views
26
CrossRef citations to date
0
Altmetric
Theme: Lipoprotein Disorders - Review

Early diagnosis and treatment of familial hypercholesterolemia: improving patient outcomes

Rodrigo Alonso Lipid Clinic, Internal Medicine Department, IIS-Fundación Jiménez Díaz, Madrid, Spain. [email protected]; Lipid Clinic, Internal Medicine Department, IIS-Fundación Jiménez Díaz, Madrid, Spain. [email protected]; Lipid Clinic, Internal Medicine Department, IIS-Fundación Jiménez Díaz, Madrid, Spain. [email protected]
,
Pedro Mata Lipid Clinic, Internal Medicine Department, IIS-Fundación Jiménez Díaz, Madrid, Spain; Spanish Familial Hypercholesterolemia Foundation, Madrid, Spain; Lipid Clinic, Internal Medicine Department, IIS-Fundación Jiménez Díaz, Madrid, Spain
,
Daniel Zambón Lipid Clinic, Endocrinology Department (ICMDM), (IDIBAPS) Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain; Lipid Clinic, Endocrinology Department (ICMDM), (IDIBAPS) Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
,
Nelva Mata Department of Epidemiology, Madrid Health Authority, Madrid, Spain; Department of Epidemiology, Madrid Health Authority, Madrid, Spain
&
Francisco Fuentes-Jiménez Lipid & Atherosclerosis Unit. IMIBIC/Reina Sofia University Hospital/University of Cordoba, Córdoba, Spain; Lipid & Atherosclerosis Unit. IMIBIC/Reina Sofia University Hospital/University of Cordoba, Córdoba, Spain
Pages 327-342 | Published online: 10 Jan 2014

References

  • Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: The Metabolic and Molecular Basis of Inherited Disease (Volume II). Scriver CR, Beaudet AL, Sly WS, Valle D (Eds). McGraw-Hill, NY, USA, 2863–2913 (2001).
  • World Health Organization. Familial Hypercholesterolemia: report of a WHO consultation, World Health Organisation, Human Genetics programme, Division of Noncommunicable Diseases. (WHO/HGN/FH/CONS/98.7, Paris 1997).
  • Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 142(1), 105–112 (1999).
  • Leigh SE, Foster AH, Whittall RA, Hubbart CS, Humphries SE. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann. Hum. Genet. 72(Pt 4), 485–498 (2008).
  • Palacios L, Grandoso L, Cuevas N et al. Molecular characterization of familial hypercholesterolemia in Spain. Atherosclerosis 221(1), 137–142 (2012).
  • Innerarity TL, Weisgraber KH, Arnold KS et al. Familial defective apolipoprotein B100: low density lipoproteins with abnormal receptor binding. Proc. Natl Acad. Sci. USA 84(19), 6919–6923 (1987).
  • Fouchier SW, Kastelein JJ, Defesche JC. Update of the molecular basis of familial hypercholesterolemia in The Netherlands. Hum. Mutat. 26(6), 550–556 (2005).
  • Abifadel M, Varret M, Rabès JP et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34(2), 154–156 (2003).
  • Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354(12), 1264–1272 (2006).
  • Soutar AK, Naoumova RP. Autosomal recessive hypercholesterolemia. Semin. Vasc. Med. 4(3), 241–248 (2004).
  • Lansberg PJ, Tuzgöl S, van de Ree MA, Defesche JC, Kastelein JJ. [Higher prevalence of familial hypercholesterolemia than expected in adult patients of four family practices in Netherlands]. Ned. Tijdschr. Geneeskd. 144(30), 1437–1440 (2000).
  • Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J. Clin. Endocrinol. Metab. 97(11), 3956–3964 (2012).
  • Leitersdorf E, Tobin EJ, Davignon J, Hobbs HH. Common low-density lipoprotein receptor mutations in the French Canadian population. J. Clin. Invest. 85(4), 1014–1023 (1990).
  • Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am. J. Epidemiol. 160(5), 407–420 (2004).
  • Meriño-Ibarra E, Castillo S, Mozas P et al.; Spanish Group of Familial Hypercholesterolemia. Screening of APOB gene mutations in subjects with clinical diagnosis of familial hypercholesterolemia. Hum. Biol. 77(5), 663–673 (2005).
  • Humphries SE, Whittall RA, Hubbart CS et al.; Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee. Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J. Med. Genet. 43(12), 943–949 (2006).
  • Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 2(7635), 1380–1382 (1969).
  • Alonso R, Mata N, Castillo S et al.; Spanish Familial Hypercholesterolaemia Group. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis 200(2), 315–321 (2008).
  • Hopkins PN, Stephenson S, Wu LL, Riley WA, Xin Y, Hunt SC. Evaluation of coronary risk factors in patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol. 87(5), 547–553 (2001).
  • Miettinen TA, Gylling H. Mortality and cholesterol metabolism in familial hypercholesterolemia. Long-term follow-up of 96 patients. Arteriosclerosis 8(2), 163–167 (1988).
  • Scientific Steering Committee on behalf of the Simon Broome Register Group. The risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 303, 893–896 (1991).
  • Neil A, Cooper J, Betteridge J et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur. Heart J. 29(21), 2625–2633 (2008).
  • Versmissen J, Oosterveer DM, Yazdanpanah M et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 337, a2423 (2008).
  • Civeira F; International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 173(1), 55–68 (2004).
  • de Groot E, Hovingh GK, Wiegman A et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 109(23 Suppl. 1), III33–III38 (2004).
  • Junyent M, Gilabert R, Zambón D et al. Femoral atherosclerosis in heterozygous familial hypercholesterolemia: influence of the genetic defect. Arterioscler. Thromb. Vasc. Biol. 28(3), 580–586 (2008).
  • Schmitz SA, O’Regan DP, Fitzpatrick J et al. Quantitative 3T MR imaging of the descending thoracic aorta: patients with familial hypercholesterolemia have an increased aortic plaque burden despite long-term lipid-lowering therapy. J. Vasc. Interv. Radiol. 19(10), 1403–1408 (2008).
  • Caballero P, Alonso R, Rosado P et al. Detection of subclinical atherosclerosis in familial hypercholesterolemia using non-invasive imaging modalities. Atherosclerosis 222(2), 468–472 (2012).
  • Min JK, Shaw LJ, Berman DS. The present state of coronary computed tomography angiography a process in evolution. J. Am. Coll. Cardiol. 55(10), 957–965 (2010).
  • Miname MH, Ribeiro MS 2nd, Parga Filho J et al. Evaluation of subclinical atherosclerosis by computed tomography coronary angiography and its association with risk factors in familial hypercholesterolemia. Atherosclerosis 213(2), 486–491 (2010).
  • Neefjes LA, Ten Kate GJ, Alexia R et al. Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolemia. Atherosclerosis 219(2), 721–727 (2011).
  • Jansen AC, van Aalst-Cohen ES, Tanck MW et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J. Intern. Med. 256(6), 482–490 (2004).
  • Nenseter MS, Lindvig HW, Ueland T et al. Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia. Atherosclerosis 216(2), 426–432 (2011).
  • Alonso R, Mata N, Cebolla H et al. Role of lipoprotein(a) as a predictor of cardiovascular disease in familial hypercholesterolemia; an analysis of the spanish FH Registry (SAFEHEART). Presented at: XVI International Symposium on Atherosclerosis. Sydney, Australia, 25–29 March 2012.
  • Campagna F, Martino F, Bifolco M et al. Detection of familial hypercholesterolemia in a cohort of children with hypercholesterolemia: results of a family and DNA-based screening. Atherosclerosis 196(1), 356–364 (2008).
  • Huijgen R, Hutten BA, Kindt I, Vissers MN, Kastelein JJ. Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH. Circ. Cardiovasc. Genet. 5(3), 354–359 (2012).
  • Descamps OS, Leysen X, Van Leuven F, Heller FR. The use of Achilles tendon ultrasonography for the diagnosis of familial hypercholesterolemia. Atherosclerosis 157(2), 514–518 (2001).
  • Mata N, Alonso R, Badimón L et al. Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). Lipids Health Dis. 10, 94 (2011).
  • Civeira F, Castillo S, Alonso R et al.; Spanish Familial Hypercholesterolemia Group. Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation. Arterioscler. Thromb. Vasc. Biol. 25(9), 1960–1965 (2005).
  • Oosterveer DM, Versmissen J, Yazdanpanah M, Hamza TH, Sijbrands EJ. Differences in characteristics and risk of cardiovascular disease in familial hypercholesterolemia patients with and without tendon xanthomas: a systematic review and meta-analysis. Atherosclerosis 207(2), 311–317 (2009).
  • Williams RR, Hunt SC, Schumacher MC et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am. J. Cardiol. 72(2), 171–176 (1993).
  • Goldberg AC, Hopkins PN, Toth PP et al.; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5(Suppl. 3), S1–S8 (2011).
  • Wierzbicki AS, Humphries SE, Minhas R; Guideline Development Group. Familial hypercholesterolaemia: summary of NICE guidance. BMJ 337, a1095 (2008).
  • World Health Organization. Familial Hypercholesterolemia: report of a second WHO consultation, World Health Organisation, Human Genetics programme, Division of Noncommunicable Diseases. World Health Organization, Geneva, Switzerland (1999) (Who publication no. WHO7HGN/FH/CONS/99.2).
  • Damgaard D, Larsen ML, Nissen PH et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 180(1), 155–160 (2005).
  • Civeira F, Ros E, Jarauta E et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am. J. Cardiol. 102(9), 1187–1193, 1193.e1 (2008).
  • Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 223(2), 262–268 (2012).
  • Neil HA, Hammond T, Huxley R, Matthews DR, Humphries SE. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 321(7254), 148 (2000).
  • Leren TP, Finborud TH, Manshaus TE, Ose L, Berge KE. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet. 11(1), 26–35 (2008).
  • Leren TP, Berge KE. Subjects with molecularly defined familial hypercholesterolemia or familial defective apoB100 are not being adequately treated. PLoS ONE 6(2), e16721 (2011).
  • Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in The Netherlands. Lancet 357(9251), 165–168 (2001).
  • Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost–effectiveness analysis. Health Technol. Assess. 4(29), 1–123 (2000).
  • Oliva J, López-Bastida J, Moreno SG, Mata P, Alonso R. [Cost–effectiveness analysis of a genetic screening program in the close relatives of Spanish patients with familial hypercholesterolemia.] Rev. Esp. Cardiol. 62(1), 57–65 (2009).
  • Defesche JC. Defining the challenges of FH screening for familial hypercholesterolemia. J. Clin. Lipidol. 4(5), 338–341 (2010).
  • Pocovi M, Civeira F, Alonso R, Mata P. Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects. Semin. Vasc. Med. 4(1), 67–74 (2004).
  • Alonso R, Defesche JC, Tejedor D et al. Genetic diagnosis of familial hypercholesterolemia using a DNA-array based platform. Clin. Biochem. 42(9), 899–903 (2009).
  • Sozen M, Whittall R, Humphries SE. Mutation detection in patients with familial hypercholesterolaemia using heteroduplex and single strand conformation polymorphism analysis by capillary electrophoresis. Atheroscler. Suppl. 5(5), 7–11 (2004).
  • van Aalst-Cohen ES, Jansen AC, Tanck MW et al. Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. Eur. Heart J. 27(18), 2240–2246 (2006).
  • Silva S, Alves AC, Patel D, Malhó R, Soutar AK, Bourbon M. In vitro functional characterization of missense mutations in the LDLR gene. Atherosclerosis 225(1), 128–134 (2012).
  • Etxebarria A, Palacios L, Stef M et al. Functional characterization of splicing and ligand-binding domain variants in the LDL receptor. Hum. Mutat. 33(1), 232–243 (2012).
  • Mata N, Alonso R, Banegas JR, Zambón D, Brea A, Mata P. Quality of life in a cohort of familial hypercholesterolemia patients from the south of Europe. Eur. J. Public Health doi:10.1093/eurpub/cks174 (2012) (Epub ahead of print).
  • Wald DS, Bestwick JP, Wald NJ. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ 335, 599 (2007).
  • Wiegman A, Rodenburg J, de Jongh S et al. Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children. Circulation 107(11), 1473–1478 (2003).
  • Watts GF, Sullivan DR, Poplawski N et al.; Familial Hypercholesterolaemia Australasia Network Consensus Group (Australian Atherosclerosis Society). Familial hypercholesterolaemia: a model of care for Australasia. Atheroscler. Suppl. 12(2), 221–263 (2011).
  • Descamps OS, Tenoutasse S, Stephenne X et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis 218(2), 272–280 (2011).
  • Kusters DM, de Beaufort C, Widhalm K et al. Paediatric screening for hypercholesterolaemia in Europe. Arch. Dis. Child. 97(3), 272–276 (2012).
  • Robinson JG, Goldberg AC. Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5(Suppl.3), s18–s29(2011).
  • Baigent C, Blackwell L, Emberson J et al.; Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670–1681 (2011).
  • Kroon AA, Aengevaeren WR, van der Werf T et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 93(10), 1826–1835 (1996).
  • Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357(9256), 577–581 (2001).
  • Alonso R, Mata P, De Andres R, Villacastin BP, Martínez-González J, Badimon L. Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin. Atherosclerosis 157(2), 423–429 (2001).
  • Catapano AL, Reiner Z, De Backer G et al. ESC/EAS guidelines for the management of dyslipidaemias. Atherosclerosis 217, 3–46 (2011).
  • Pijlman AH, Huijgen R, Verhagen SN et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 209(1), 189–194 (2010).
  • Stein EA, Strutt K, Southworth H, Diggle PJ, Miller E; HeFH Study Group. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am. J. Cardiol. 92(11), 1287–1293 (2003).
  • Stein EA, Amerena J, Ballantyne CM et al. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia. Am. J. Cardiol. 100(9), 1387–1396 (2007).
  • Avis HJ, Hutten BA, Gagné C et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J. Am. Coll. Cardiol. 55(11), 1121–1126 (2010).
  • Gandelman K, Glue P, Laskey R, Jones J, LaBadie R, Ose L. An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia. Pediatr. Cardiol. 32(4), 433–441 (2011).
  • van der Graaf A, Cuffie-Jackson C, Vissers MN et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J. Am. Coll. Cardiol. 52(17), 1421–1429 (2008).
  • Kastelein JJ, Akdim F, Stroes ES et al.; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358(14), 1431–1443 (2008).
  • Huijgen R, Abbink EJ, Bruckert E et al.; Triple Study Group. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin. Ther. 32(4), 615–625 (2010).
  • Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study. Cardiovasc. Drugs Ther. 19(6), 403–414 (2005).
  • Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve. Clin. J. Med. 78(6), 393–403 (2011).
  • Gagné C, Bays HE, Weiss SR et al.; Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. 90(10), 1084–1091 (2002).
  • Musa-Veloso K, Poon TH, Elliot JA, Chung C. A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials. Prostaglandins Leukot. Essent. Fatty Acids 85(1), 9–28 (2011).
  • Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210(2), 353–361 (2010).
  • Jacobson TA. Myopathy with statin-fibrate combination therapy: clinical considerations. Nat. Rev. Endocrinol. 5(9), 507–518 (2009).
  • Thompson GR, Catapano A, Saheb S et al. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr. Opin. Lipidol. 21(6), 492–498 (2010).
  • Graesdal A, Boqsrud MP, Holven KB et al. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J. Clin. Lipidol. 6, 331–339 (2012).
  • Avis HJ, Vissers MN, Stein EA et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 27(8), 1803–1810 (2007).
  • O’Gorman CS, Higgins MF, O’Neill MB. Systematic review and meta-analysis of statins for heterozygous familial hypercholesterolemia in children: evaluation of cholesterol changes and side effects. Pediatr. Cardiol. 30(4), 482–489 (2009).
  • Vuorio A, Docherty KF, Humphries SE, Kuoppala J, Kovanen PT. Statin treatment of children with familial hypercholesterolemia – trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? Atherosclerosis 226(2), 315–320 (2012).
  • Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 128, S213–S256 (2011).
  • Cuchel M, Bloedon LT, Szapary PO et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med. 356(2), 148–156 (2007).
  • Cuchel M, Mehageer EA, du Toit Theron H et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, Phase 3 study. Lancet 381(9860), 40–46 (2012).
  • Visser ME, Witztum JL, Stroes ES, Kastelein JJ. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur. Heart J. 33(12), 1451–1458 (2012).
  • Akdim F, Visser ME, Tribble DL et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am. J. Cardiol. 105(10), 1413–1419 (2010).
  • Raal FJ, Santos RD, Blom DJ et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375(9719), 998–1006 (2010).
  • Yu RZ, Geary RS, Flaim JD et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2’-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B100 messenger RNA, with simvastatin and ezetimibe. Clin. Pharmacokinet. 48(1), 39–50 (2009).
  • Visser ME, Akdim F, Tribble DL et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J. Lipid Res. 51(5), 1057–1062 (2010).
  • Stein EA, Mellis S, Yancopoulos GD et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366(12), 1108–1118 (2012).
  • Stein EA, Gipe D, Bergeron J et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a Phase 2 randomised controlled trial. Lancet 380(9836), 29–36 (2012).
  • Dias CS, Shaywitz AJ, Wasserman SM et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose Phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J. Am. Coll. Cardiol. 60(19), 1888–1898 (2012).
  • Raal F, Scott R, Somaratne R et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 126(20), 2408–2417 (2012).
  • Barter PJ, Caulfield M, Eriksson M et al.; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357(21), 2109–2122 (2007).
  • Schwartz GG, Olsson AG, Ballantyne CM et al.; dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am. Heart J. 158(6), 896–901.e3 (2009).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.